Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Patrick Mahomes Signs With Logan Paul-Backed PRIME Drink Company: Why This Could Be Bad News For Coca-Cola And Pepsi

Published 19/12/2023, 21:09
Updated 19/12/2023, 22:10
© Reuters.  Patrick Mahomes Signs With Logan Paul-Backed PRIME Drink Company: Why This Could Be Bad News For Coca-Cola And Pepsi

Benzinga - by Chris Katje, Benzinga Staff Writer.

Sports and energy drink brand PRIME continues to see strong growth. The addition of another key athlete to its endorsement library could strengthen the brand going forward, putting concern on Coca-Cola Inc (NYSE:KO) and PepsiCo (NYSE:PEP) — two companies that have dominated the sports drink market for many years.

What Happened: One month after announcing the company hit one billion lifetime units sold, PRIME is back with another company announcement that could show off its strong growth profile and competition to legacy beverage companies.

On Monday, PRIME announced it has signed Kansas City Chiefs quarterback Patrick Mahomes as one of the company's PRIME Hydration Athletes.

"As a PRIME athlete, Mahomes will collaborate with the brand's team across social media, special events, charitable activations and more," the company said.

Mahomes is one of the top players in the NFL, winner of two Super Bowls, two Super Bowl MVPs and two regular season MVP awards in his short career.

"PRIME is a disruptive brand that has taken over the beverage industry since its first launched. They are gamechangers, and that's exactly what I strive to be on the field," Mahomes said. "Our partnership is a winning play, merging innovation and excellence, setting a new standard both on and off the field."

PRIME was launched in January 2022 by popular YouTubers Logan Paul and KSI. The brand has become one of the fastest-growing beverage brands.

"It's a privilege to welcome Patrick Mahomes to the PRIME family and we can't wait for you to see what we have planned in 2024," Paul and KSI said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Related Link: 5 Things You Might Not Know About Kansas City Chiefs QB Patrick Mahomes

Why It's Important: The addition of Mahomes to the brand adds to a lineup that includes soccer star Erling Haaland (Manchester City), NHL star Auston Matthews (Toronto Maple Leafs) and several UFC fighters like Alexander Volkanovski and Israel Adesanya.

PRIME also has deals in place with the UFC, soccer teams Arsenal, FC Barcelona and Bayern Munich and MLB team the Los Angeles Dodgers.

In its first year, PRIME hit $250 million in retail sales. The company has hit $1.2 billion in internal sales through the end of 2023. Key retail stores like Target, GNC, Kroger and Walmart carry the brand.

Its caffeinated beverage, PRIME Energy, launched in 2023.

PRIME competes with Coca-Cola and Pepsi in both sports drinks and energy drinks. Coca-Cola owns the Powerade, BodyArmor and Vitamin Water brands. It also has a strong position in the energy drink sector, thanks to its equity stake and distribution of Monster Beverage (NASDAQ:MNST).

PepsiCo owns Gatorade, which dominates the sports drink market. It also made a major investment in fast-growing energy drink brand Celsius Holdings (NASDAQ:CELH).

Data shared by Darren Rovell shows PRIME with growth outpacing the beverage giants. Here's a look at the last 52 week sales of top sports drink brands through Oct. 8, 2023.

  • Gatorade: $7.1 billion, +7% year-over-year
  • BodyArmor: $1.4 billion, -11%
  • Powerade: $1.2 billion, +0.4%
  • PRIME: $565 million, +896%
  • Electrolit: $425 million, +21%
  • Keurig Dr Pepper Inc

    Mahomes’ teaming up with PRIME could be a touchdown for the drink brand. It may also put further pressure on Coca-Cola and Pepsi moving forward.

    3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

    Read Next: Logan Paul’s PRIME Energy Drink Answers Chuck Schumer’s Call For An FDA Investigation

    Image: Shutterstock

    © 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Read the original article on Benzinga

    Latest comments

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.